IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. - Wikidata - awgldk - TriplyDB

IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting.

IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting.

http://www.wikidata.org/entity/Q37123224

about

Aerobic Exercise and Pharmacological Therapies for Skeletal Myopathy in Heart Failure: Similarities and Differences Nonmuscle Tissues Contribution to Cancer Cachexia Interleukin-6 myokine signaling in skeletal muscle: a double-edged sword?Current status of bicarbonate in CKD Inflammation-induced acute phase response in skeletal muscle and critical illness myopathy Uremic myopathy: is oxidative stress implicated in muscle dysfunction in uremia?Tumor necrosis factor-α regulates distinct molecular pathways and gene networks in cultured skeletal muscle cells Ghrelin prevents tumour- and cisplatin-induced muscle wasting: characterization of multiple mechanisms involved.Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy Potential involvement of P2Y2 receptor in diuresis of postobstructive uropathy in rats.Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease.IGF-1 prevents ANG II-induced skeletal muscle atrophy via Akt- and Foxo-dependent inhibition of the ubiquitin ligase atrogin-1 expression.Clinical development of ghrelin axis-derived molecules for cancer cachexia treatment Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the antidiabetes drug berberine.Glucocorticoids increase adipocytes in muscle by affecting IL-4 regulated FAP activity.Shorter telomeres in peripheral blood mononuclear cells from older persons with sarcopenia: results from an exploratory study Angiotensin type 2 receptor signaling in satellite cells potentiates skeletal muscle regeneration.Macrophage-stimulated cardiac fibroblast production of IL-6 is essential for TGF β/Smad activation and cardiac fibrosis induced by angiotensin II Angiotensin II modulates mouse skeletal muscle resting conductance to chloride and potassium ions and calcium homeostasis via the AT1 receptor and NADPH oxidase IL-6 signaling blockade increases inflammation but does not affect muscle function in the mdx mouse.Melanocortin antagonism ameliorates muscle wasting and inflammation in chronic kidney disease.Akt1-mediated fast/glycolytic skeletal muscle growth attenuates renal damage in experimental kidney disease.Myostatin suppression of Akirin1 mediates glucocorticoid-induced satellite cell dysfunction.Mechanisms of muscle wasting in chronic kidney disease Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension.Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease.Protein phosphatase 2C-alpha knockdown reduces angiotensin II-mediated skeletal muscle wasting via restoration of mitochondrial recycling and function Angiotensin II induced catabolic effect and muscle atrophy are redox dependent.Delving into disability in Crohn's disease: dysregulation of molecular pathways may explain skeletal muscle loss in Crohn's disease.Low-frequency electrical stimulation attenuates muscle atrophy in CKD--a potential treatment strategy XIAP reduces muscle proteolysis induced by CKD.Angiotensin II upregulates protein phosphatase 2Cα and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia Decreased miR-29 suppresses myogenesis in CKD.Cachexia and protein-energy wasting in children with chronic kidney disease.The TWEAK-Fn14 system: breaking the silence of cytokine-induced skeletal muscle wasting.Targeting the myostatin signaling pathway to treat muscle wasting diseases Angiotensin II reduces food intake by altering orexigenic neuropeptide expression in the mouse hypothalamus.Role of integrin-β3 protein in macrophage polarization and regeneration of injured muscle Serum Amyloid A Induces Toll-Like Receptor 2-Dependent Inflammatory Cytokine Expression and Atrophy in C2C12 Skeletal Muscle Myotubes.

P2860

Q26767412-E56DFCA5-D2D2-44E1-84AA-D6BC05B45571 Q26777562-09521C1D-EEF3-44FB-99CD-6E056A992ED9 Q26866208-6CF1FED0-5707-4976-96C3-A93B3DE2DA9F Q27015082-59456C05-6656-4DF9-B89E-5A8A15F5C814 Q27314918-7858893E-4910-4BF3-8F18-B9678BB71EFA Q28084066-086AF86F-84E7-4033-BA4D-D4C615FCED92 Q28475735-2E77A040-77F1-4236-8BB0-8E5D103FB51B Q30384810-50D61B5E-4935-4269-8B8D-10D3F002E460 Q33702390-517A4E88-FAC9-4577-846B-D942FA8EBFF8 Q33727799-7F33C85E-5FE6-45B3-AF5E-D6A36A6BAFE0 Q33802142-B94C6EFB-F331-413C-B341-E899718516C8 Q33840703-D53BD0D6-8446-4ED9-8145-3A7AA7E18623 Q34002674-B8A31577-AAB5-4D6A-9E51-F296C0A232B3 Q34024390-7CEECADD-BEAF-42BE-A4BC-361D2D46C7CE Q34072671-309C582A-161A-4C8D-9EF9-90C018898913 Q34102906-5328F6DD-42DC-4A84-918F-F55D12A42271 Q34248966-39DAD8B6-C6E9-4C39-A40C-FC14C03A4547 Q34264496-1AEBEB4E-C9B0-4B61-BE05-27C18D4125A1 Q34295366-8EE45DEA-EBC3-43A9-B01E-960434223632 Q34310898-F4F64ADF-79ED-44FC-9523-BFD9A9D64633 Q34390204-4DEA04BB-FF8D-4882-A81D-0DED1D015DC0 Q34568763-B88FEE32-8405-4580-8167-3EDAE1C7153D Q34629780-FB995352-4D12-4E94-91BC-374ED364A21B Q34723810-55B55E7D-B4B1-45FD-8E3B-2DEE622E8E5D Q34726868-5A432DC8-6B6C-4A28-98AD-8E4E1DAAE0FA Q34813421-B9947EDD-67C7-47DD-ABE1-9E125C46CC01 Q35011884-4F5F6162-61B5-4FDF-9976-F3D45DA8FDD8 Q35028013-A0934E7E-3F2A-48AA-876B-8224D8CFFE2B Q35065914-2F28923F-0E93-4B1A-B2F7-F7140A737BB3 Q35124242-F687400D-61E5-48DE-97C0-434C81C2FBD5 Q35153178-AEA23306-B7E8-4F9C-991E-87748E982D53 Q35240148-DB693E42-7566-4F94-B996-8E1FC990897C Q35536351-5E9580F1-64D2-4713-812B-8DE82914F24A Q35595507-2F51D1E9-87E5-4621-A151-5CE6EAEFA9CE Q35645564-47D229C5-215B-483F-9FC0-ACB358F75E7C Q35671234-E153BC81-BD0C-41B3-A068-5360A42A4A79 Q35739702-C7D82F90-A1F0-40CF-B7B8-C94F75F7B878 Q35762656-DDA40167-9D90-46CB-92A5-487417009909 Q35838867-3AAD820F-7D71-4690-8B0B-E0BFBD5A7505 Q35897585-2F81FE11-E657-4A7A-BFBA-A25DCC856B55

P2860

IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting.

http://www.wikidata.org/entity/Q37123224

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 21 January 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting.

@en

IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting.

@nl

type

label

IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting.

@en

IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting.

@nl

prefLabel

IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting.

@en

IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting.

@nl

P1433

Q37123224-E737F9C7-29BD-4917-A74D-0D0BF16F80B1

P1476

Q37123224-F8560839-6576-4AF5-B072-3F72212479E5

P2093

Q37123224-21426016-E89C-48BE-9019-079EF35C2145

Q37123224-5AF7A5E8-B91A-4CFE-B1A4-672986586B6B

Q37123224-5D58F2EA-1226-4D75-846F-CE799D0C0B4A

Q37123224-90E2A55A-BB25-452C-B688-62663960072B

Q37123224-BB742BB5-500F-4CE7-BEB1-D75DCE659A9D

Q37123224-C0F15F8E-372E-4872-9A9A-58D5A11DAEF9

P2860

Q37123224-06FB0B64-8155-4B66-A6A3-371A83D80131

Q37123224-29AF49E3-AA46-4B53-BD66-16F7000343F1

Q37123224-2F1CB3C4-1848-4209-880B-0CA807785E9C

Q37123224-35534FAD-5625-4018-944A-6AE12A87C87B

Q37123224-36E306D6-844D-4E7D-94AF-4986AFD7E949

Q37123224-37AA53C0-A5B0-4263-86C2-86E513A8BC1F

Q37123224-3A66BB92-0CC7-4C8E-A8B9-F01CE4D4BFAA

Q37123224-4040B3BC-2CF5-4355-A1AA-6A5F697D7277

Q37123224-4386F2DF-B2EF-4413-B23E-BFCE0F21C94F

Q37123224-4F53CF46-FC6F-4560-A2F8-54D84B55122F

P304

Q37123224-5E00A7E3-4535-4E7C-92A5-51CFF04C7D0F

P31

Q37123224-6941ACDF-B747-4872-9CEF-67517C910275

P356

Q37123224-F1600EEE-B59A-4BB6-AC8A-B614CFFCFC6F

P433

Q37123224-30A99A11-0319-43F0-AD11-8BE425B28746

P478

Q37123224-16C57DB4-D997-47F8-8270-F5C255D2EE74

P50

Q37123224-26B189A3-6F28-4919-AA27-48C072AF78FC

P577

Q37123224-7675094A-5741-4D55-BED1-C84CB182E4D5

P698

Q37123224-3EC7BABA-5C2F-4DCA-A30B-1B7A0A172F5F

P932

Q37123224-4AA2A69D-581B-4E17-97B4-F641A79B35A6

P356

P1433

Journal of the American Society of Nephrology

P1476

IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting.

@en

P2093

Gabriela Garcia

http://www.w3.org/2001/XMLSchema#string

Guofeng Han

http://www.w3.org/2001/XMLSchema#string

Jie Du

http://www.w3.org/2001/XMLSchema#string

Liping Zhang

http://www.w3.org/2001/XMLSchema#string

William E Mitch

http://www.w3.org/2001/XMLSchema#string

Zhaoyong Hu

http://www.w3.org/2001/XMLSchema#string

P2860

Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy

Human Serum Amyloid A Protein Inhibits Hepatitis C Virus Entry into Cells

Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action

SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2

Identification of ubiquitin ligases required for skeletal muscle atrophy

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy

IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance

Characterization of two new members of the formyl peptide receptor gene family from 129S6 mice.

Adenosine A2A receptor activation and macrophage-mediated experimental glomerulonephritis.

P304

604-612

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1681/ASN.2008060628

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Patrice Delafontaine

P577

2009-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19158350

http://www.w3.org/2001/XMLSchema#string

P932

2653674

http://www.w3.org/2001/XMLSchema#string